The FDA has approved Novo Nordisk's once-weekly GLP-1 receptor agonist Ozempic (semaglutide) to improve glycemic control in adults with type 2 diabetes. Based on the SUSTAIN Phase 3a clinical trial program involving over 8,000 adults, the drug demonstrated superior A1c reductions compared to sitagliptin and exenatide extended-release, as well as significant weight loss as a secondary benefit. The drug will be available in 0.5 mg and 1 mg pre-filled pen doses.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.